Page last updated: 2024-11-08

bucumolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

bucumolol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID169787
CHEMBL ID349807
CHEBI ID135297
SCHEMBL ID78558
MeSH IDM0082185

Synonyms (19)

Synonym
58409-59-9
bucumolol
bucumolol [inn]
CHEBI:135297
CHEMBL349807
8-[3-(tert-butylamino)-2-hydroxypropoxy]-5-methylchromen-2-one
8-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-5-methyl-2h-1-benzopyran-2-one
(rs)-8-(3-(tert-butylamino)-2-hydroxyproproxy)-5-methylcoumarin
8-(3-(tert-butylamino)-2-hydroxypropoxy)-5-methylcoumarin
bucumololum
unii-u8wvj3501l
bucumololum [inn-latin]
u8wvj3501l ,
bucumolol [who-dd]
bucumolol [mi]
SCHEMBL78558
Q15634022
DTXSID00866688
8-[3-(tert-butylamino)-2-hydroxypropoxy]-5-methyl-2h-1-benzopyran-2-one

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with bucumolol at 2.5 mg/Kg s.c."( Effects of bucumolol, a beta-adrenergic blocking agent, and its d-isomer on myocardial infarction produced by coronary artery ligation in rats.
Koike, H; Kumakura, S; Minato, S; Nishino, H; Tamaoki, H, 1981
)
0.98
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]